Global Market for DNA Sequencing Worth $1.7 Billion by 2013

August 11, 2008

Wellesley, Mass—According to a new technical market research report, DNA SEQUENCING: EMERGING TECHNOLOGIES AND APPLICATIONS (BIO045B) from BCC Research, the global market for DNA sequencing technology was worth $794.0 million in 2007 and an estimated $862.5 million in 2008. This should increase to $1.7 billion by 2013, a compound annual growth rate (CAGR) of 14.7%.

The market is broken down into the segments of research/drug discovery and development, commercial applications and emerging applications. Research/drug discovery and development has the largest share of the market, generating $600.4 million in 2007. This is expected to increase to $640.6 million in 2008 and over $1.0 billion in 2013, for a CAGR of 9.7%.

Commercial applications have the next largest share of the market, worth $193.6 million in 2007 and an estimated $218.8 million in 2008. This should increase at a CAGR of 14.3% to reach $426.1 million in 2013.

Emerging applications have the smallest but fastest growing share of the market. This sector is expected to generate $3.1 million by the end of 2008 and $272.5 million in 2013, for a CAGR of 144.8%.

DNA sequencing allows us to catalogue the variations within the human genome sequence that make us phenotypically different, and that cause resistance and susceptibility to disease. The rapidly evolving sequencing technologies provide unprecedented analytical tools that allow us to identify this sequence variation, in humans as well as in other species.

Technology and market forces are working a fundamental shift in the DNA sequencing industry away from stagnant/declining growth towards high growth. This growth inflection signals the arrival of DNA sequencing as a premier genetic analysis tool: useful for existing applications such as de novo whole genome sequencing and entirely new applications like epigenetic tag sequencing.

FIGURE
GLOBAL VALUE OF DNA SEQUENCING, BY END USE APPLICATION,
2006-2013
($ millions)

read more | digg story

Bookmark and Share

Advertisements

Non Drug Discovery Topics at DDT Boston

August 8, 2008

In addition to the discussion and exhibition of novel drug discovery technologies at the annual Drug Discovery Conference in Boston this week, a number of informal talks with attendees centered around creating drug/device combination products and performing QA/QC of biotherapeutics. Both are activities that take place well beyond drug discovery operations in new drug development.

BCC Research estimates that the total market for drug-device combinations was $5.4 billion in 2004 and is expected to rise at an average annual growth rate of 13.6% to $11.5 billion in 2010. The key category is drug-eluting stent market which could total $8 billion in two years.¹

¹John Sterling, Editor-in-Chief, Genengnews.com

read more | digg story

Bookmark and Share


Eastman launches controlled-release excipient

July 17, 2008

A new excipient could help drugmakers improve the delivery profiles of active pharmaceutical ingredients (API), according to US developer Eastman Chemical.¹

¹OutsourcingPharma.com

read more | digg story

Bookmark and Share


Global Market for Cancer Therapies Slated for High Growth Through 2013

July 16, 2008

WELLESLEY, Mass., July 16, 2008–According to a new technical market research report, CANCER THERAPIES: TECHNOLOGIES AND GLOBAL MARKETS (HLC027B) from BCC Research, the global market for cancer therapies will be worth $47.3 billion in 2008. This should increase to over $110.6 billion by 2013, a compound annual growth rate (CAGR) of 12.6%.

The four main types of cancer therapy are chemotherapy, hormone therapy, target therapy and immunotherapy. Of these, the target therapy segment has the largest share of the market. Worth an estimated $22.9 billion in 2008, this segment should reach $69.1 billion in 2013, for a CAGR of 24.7%. Target therapy comprised approximately 45.0% of the overall market in 2007. This figure is expected to increase to 48.0% by the end of 2008 and 62.5% in 2013.

Chemotherapy has the second largest share of the market, worth $13.1 billion in 2007. This segment is expected to reach $14.3 billion in 2008 and $24.3 billion in 2013, for a CAGR of 11.2%.

The breast cancer therapy segment dominated the overall market in 2007 with 26.0% of the market share and $10.6 billion in revenue. This segment is forecast to reach $12.4 billion in 2008 and $26.5 billion in 2013, for a CAGR of 16.4%.

Although significant improvements in the diagnosis and development of various compounds to treat cancer have been made, cancer remains a major healthcare challenge worldwide. More than 11 million people are diagnosed with cancer every year, and the cancer therapy market is the second largest pharmaceutical market in terms of revenue after the cardiovascular drug market.

Data and analysis extracted from this press release must be accompanied by a statement identifying

BCC Research (www.bccresearch.com), 40 Washington Street, Suite 110, Wellesley, MA;
Telephone: 866-285-7215, editor@bccresearch.com as the source and publisher.

Additional Releases: http://www.bccresearch.com/press.htm

BCC Research is a leading publisher of market research reports and technical publications. Forthcoming report information can be found on our Web site at http://www.bccresearch.com

Contact:
Jason W. Prokowiew
Tel: 978-870-3345
Email: jason.prokowiew@bccresearch.com

read more | digg story

Bookmark and Share


BASF signs up to USP certification scheme

June 23, 2008

BASF’s drug excipient manufacturing site in Geismar, Louisiana in the USA has been accredited under the US Pharmacopoeia’s (USP) voluntary certification scheme. ¹

¹Gareth Macdonald, In-pharma Technologist.com

read more | digg story

Bookmark and Share


Incredible Growth Potential in Pharmaceuticals Market

June 11, 2008

The market is broken down into applications of branded prescription drugs, generic prescription drugs and over-the-counter (OTC) products. Of these, branded prescription drugs have the largest share of the market. Worth an estimated $525.1 billion in 2007, this segment is expected to grow to a value of $553.2 billion in 2008.¹

¹Pharma Live

read more | digg story

Bookmark and Share


Value ‘add’itives

April 21, 2008

Additives are key ingredients of most medicines. This may be the reason why additives have been inseparable from pharma industry despite having a few drawbacks. Sachin Jagdale provides more details.¹

read more | digg story

¹ExpressPharmaOnline.com

Bookmark and Share
StumbleUpon